Gyre Therapeutics (GYRE) Net Income towards Common Stockholders Growth (3y) (2013 - 2026)
Gyre Therapeutics (GYRE) Net Income towards Common Stockholders Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.30% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.23% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 71.02% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 37.89% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.99% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -38.56% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 37.44% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 62.15% |
| 10 | Gyre Therapeutics | 708.31 Mn | 685.47 Mn | 26.90 Mn | -102.42% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -102.42% |
| Mar 31, 2026 | -80.42% |
| Dec 31, 2025 | 61.38% |
| Sep 30, 2025 | 39.92% |
| Jun 30, 2025 | -79.54% |
| Mar 31, 2025 | 29.77% |
| Dec 31, 2024 | 83.23% |
| Sep 30, 2024 | 26.92% |
| Jun 30, 2024 | 29.61% |
| Mar 31, 2024 | 32.68% |
| Dec 31, 2023 | -74.81% |
| Sep 30, 2023 | 31.00% |
| Jun 30, 2023 | 28.21% |
| Mar 31, 2023 | 36.69% |
| Dec 31, 2022 | -30.01% |
| Sep 30, 2022 | 27.29% |
| Jun 30, 2022 | 79.12% |
| Mar 31, 2022 | 1.22% |
| Dec 31, 2021 | -24.66% |
| Sep 30, 2021 | -48.58% |